Ionis Pharmaceuticals (IONS) Change in Accured Expenses (2013 - 2026)

Ionis Pharmaceuticals' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $21.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 148.8% year-over-year to $21.0 million in Q1 2026; TTM through Mar 2026 was $69.4 million, a 3898.5% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, up 182.56% from the prior year.
• Change in Accured Expenses improved to $21.0 million in Q1 2026 per IONS's latest filing, from -$82.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $110.7 million in Q3 2025 and bottomed at -$82.4 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $10.5 million (2022), against an average of $1.9 million.
• Across the five-year window, Change in Accured Expenses tumbled 2653.38% in 2022 and jumped 950.6% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $18.8 million in 2022, then declined by 0.29% to $18.7 million in 2023, then surged by 63.24% to $30.5 million in 2024, then plunged by 369.58% to -$82.4 million in 2025, then soared by 125.5% to $21.0 million in 2026.
• Per Business Quant, the three latest IONS Change in Accured Expenses figures stand at $21.0 million (Q1 2026), -$82.4 million (Q4 2025), and $110.7 million (Q3 2025).